NCT06917885View on ClinicalTrials.gov

CUE-102 in Recurrent Glioblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Recurrent GlioblastomaGlioblastomaGlioma, Malignant
Interventions
BIOLOGICAL

CUE-102

A WT-1-pHLA-IL2-Fc fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.

Trial Locations (2)

02115

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Cue Biopharma
All Listed Sponsors
collaborator

Cue Biopharma

INDUSTRY

lead

David Reardon, MD

OTHER

NCT06917885 - CUE-102 in Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter